Related Experiment Video
Updated: Jul 17, 2026
Biochemical Measurement of Neonatal Hypoxia
Published on: August 24, 2011
Docosahexaenoic Acid Supplementation for Neonatal Hyperbilirubinemia: A Double-Blind, Randomized Clinical Trial
Yun-Qian Chi1, Yi Yao2, Wen-Hong Zhang1
1Pediatric Department, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Insights
Docosahexaenoic acid (DHA) supplementation may protect newborns from brain damage caused by high bilirubin levels (hyperbilirubinemia). This study found DHA reduced injury markers and improved outcomes in infants with neonatal hyperbilirubinemia.
Area of Science:
- Neuroscience
- Biochemistry
- Neonatal Medicine
Background:
- Docosahexaenoic acid (DHA) is vital for brain development.
- Neonatal hyperbilirubinemia can cause severe neurological damage, including kernicterus.
- Previous research indicated DHA's neuroprotective effects in cell and animal models.
Purpose of the Study:
- To investigate the clinical efficacy of DHA as an adjuvant therapy for neonatal hyperbilirubinemia.
- To assess DHA's potential in reducing bilirubin-induced brain injury in infants.
Main Methods:
- A double-blind, randomized, placebo-controlled trial involving 60 infants with neonatal hyperbilirubinemia.
- Participants received either 100 mg/day DHA or a placebo syrup.
- Outcomes measured included bilirubin levels, neuron-specific enolase (NSE), phototherapy duration, and cranial MRI abnormalities.
Main Results:
- The DHA group showed significantly lower bilirubin levels at 48 hours, reduced NSE levels, and shorter phototherapy durations compared to the placebo group.
- Fewer infants in the DHA group exhibited abnormal cranial MRI findings.
- Statistical significance was observed with P < .05 for all key findings.
Conclusions:
- DHA demonstrates effectiveness as an adjuvant treatment for neonatal hyperbilirubinemia.
- DHA supplementation can mitigate the incidence and severity of bilirubin-induced brain injury in newborns.
- Further clinical research supports DHA's protective role in neonatal neurological health.
Abstract:
Docosahexaenoic acid (DHA) is an essential component for brain development during fetal and early postnatal life. Hyperbilirubinemia is characterized by abnormally high levels of bilirubin in the bloodstream, frequently leading to jaundice in newborns. In severe instances, this condition can progress to neurological damage or kernicterus, a form of brain damage. Initial cell-based experiments conducted by our research team revealed that DHA significantly enhances the survival rate of nerve cells treated with bilirubin and diminishes the oxidative stress indicated by reduced peroxide activity caused by unconjugated bilirubin (UCB). Further investigations through animal studies demonstrated that DHA effectively mitigates bilirubin-induced brain injury in neonatal rats. However, the potential of DHA to decrease the incidence of bilirubin-induced brain damage in clinical settings has not been previously explored or reported. Infants with neonatal hyperbilirubinemia (n = 30 per group) participated in a double-blind, randomized, placebo-controlled parallel study. They received either 100 mg/d DHA or placebo syrup immediately when they were diagnosed. The study found that the bilirubin level at 48 hours of treatment, serum neuron-specific enolase (NSE) levels, mean phototherapy duration, and abnormal rate of cranial magnetic resonance imaging (MRI) were lower in the DHA group than those in the control group (P < .05). These results suggested that DHA is effective as an adjuvant treatment for hyperbilirubinemia in children. It can reduce the incidence of neonatal hyperbilirubinemia brain injury and plays a certain protective role. Clinical study on protective effect of DHA on neonatal bilirubin injury is registered at Chinese Clinical Trial Registry as ChiCTR2300070250.
